Skip to main content

ACE2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 71 bp deletion in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human ACE2 knockout Hep G2 cell line (AB273733), expandable thumbnail
  • Western blot - Human ACE2 knockout Hep G2 cell line (AB273733), expandable thumbnail
  • Sanger Sequencing - Human ACE2 knockout Hep G2 cell line (AB273733), expandable thumbnail

Key facts

Cell type
Hep G2
Species or organism
Human
Tissue
Liver
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 71 bp deletion in exon 2

Alternative names

ACE-related carboxypeptidase, ACE2_HUMAN, ACEH, Angiotensin I Converting Enzyme (peptidyl dipeptidase A) 2, Angiotensin I converting enzyme 2, Angiotensin converting enzyme 2, Angiotensin converting enzyme like protein, Angiotensin-converting enzyme homolog, DKFZP434A014, EC 3.4.17, OTTHUMP00000022963, Processed angiotensin-converting enzyme 2, metalloprotease MPROT 15

Recommended products

ACE2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 71 bp deletion in exon 2.

Key facts

Cell type
Hep G2
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 71 bp deletion in exon 2
Disease
Hepatocellular Carcinoma
Concentration
Loading...

Properties

Gene name
ACE2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
MEM + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HepG2 cell line (ab257304). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The ACE2 protein also known as angiotensin-converting enzyme 2 is an essential component in the renin-angiotensin system. It functions mechanically by converting the hormone angiotensin II to angiotensin-(1-7) which helps regulate blood pressure and fluid balance. The molecular weight of ACE2 is approximately 120 kDa. This protein is expressed in various tissues particularly the lungs heart kidneys and gastrointestinal tract. In cultured cells like Caco-2 cells researchers often study this expression.

Biological function summary

The ACE2 protein plays an important role in the regulation of cardiovascular and renal functions. It is a single-pass type I membrane protein and its activity reduces inflammation and oxidative stress in cells. ACE2 does not function as part of a larger protein complex but its enzymatic conversion has a substantial impact on reducing the effects of angiotensin II in the body leading to vasodilation and decreased blood pressure.

Pathways

ACE2 involvement is significant in the renin-angiotensin system and the kallikrein-kinin system. These pathways are essential for maintaining cardiovascular homeostasis. In the renin-angiotensin system ACE2 works in opposition to angiotensin-converting enzyme (ACE) balancing the effects through the production of angiotensin-(1-7) from angiotensin II. Additionally ACE2 interacts indirectly with proteins like angiotensin receptor type 1 (AT1) and angiotensin receptor type 2 (AT2) ensuring proper signaling and physiological responses.

Associated diseases and disorders

ACE2 links closely with conditions such as hypertension and COVID-19. Increased activity of angiotensin II due to low ACE2 levels contributes to hypertension. In infectious disease SARS-CoV-2 virus responsible for COVID-19 uses ACE2 as an entry receptor to initiate infection in host cells. This interaction highlights the importance of ACE2 in disease pathogenesis and has prompted interest in ACE2 as a potential therapeutic target.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com